Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Pain, Postoperative 19Breast Neoplasms 13Brain Neoplasms 11Agnosia 7Neoplasms 6Lung Neoplasms 5Delirium 5Thyroid Neoplasms 4Stomach Neoplasms 4Pituitary Neoplasms 3Pain 3Inflammation 3Emergence Delirium 3Colorectal Neoplasms 3Chronic Pain 3Urinary Bladder Neoplasms 2Supratentorial Neoplasms 2Rectal Neoplasms 2Prostatic Neoplasms 2Pheochromocytoma 2Pain, Intractable 2Neoplasm Metastasis 2Liver Neoplasms 2Dexmedetomidine 2Colonic Neoplasms 2Central Nervous System Diseases 2Abdominal Neoplasms 2Thrombosis 1Spinal Cord Neoplasms 1Sleep Initiation and Maintenance Disorders 1

Interventions

Mifepristone 3Corlux 3Thyrotropin-Releasing Hormone 1Surgical Procedures, Operative 1Sodium Chloride 1Saline Solution 1Radiotherapy 1Radiomics 1Nivolumab 1Magnetic Resonance Spectroscopy 1LY2940680 1Ipilimumab 1Hydrocortisone 1Human Growth Hormone 1Diazoxide 1Dexmedetomidine 1Dexamethasone 1Biomarkers 1Anesthesia, Local 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pituitary Diseases × Dexmedetomidine × Clear all
NCT02549768 2016-10-12

Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery

Pontificia Universidad Catolica de Chile

Phase 4 Unknown
40 enrolled
Endocrine

Pituitary Diseases, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡